Abelacimab Evidence: Trial Results and Peer-Reviewed Publications

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

1. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
   Ruff CT, Patel SM, Giugliano RP, et al. · N Engl J Med · 2025
   PubMed: PMID 39842011 · NCT04755283 (AZALEA-TIMI 71) · Atrial Fibrillation
2. Factor XI inhibitors - Rising stars in anti-thrombotic therapy?
   Nolte CH · J Neurol Sci · 2024
   PubMed: PMID 39094433 · NCT05712200 (LILAC-TIMI 76) · Atrial Fibrillation
3. Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.
   Al Said S, Patel SM, Giugliano RP, et al. · JAMA Cardiol · 2026
   PubMed: PMID 41637102 · NCT04755283 (AZALEA-TIMI 71) · Atrial Fibrillation
4. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
   Al Said S, Patel SM, Giugliano RP, et al. · Circulation · 2025
   PubMed: PMID 40546068 · NCT04755283 (AZALEA-TIMI 71) · Atrial Fibrillation

Publications by year

2024–2026: 4 publications.

Publications by indication

Publications by journal

• N Engl J Med1 paper
• J Neurol Sci1 paper
• JAMA Cardiol1 paper
• Circulation1 paper

All Abelacimab publications (4)

Sources and methodology

• Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
• Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
• Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
• Data freshness: Thu, 14 May 2026 22:20:31 GMT.